Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hepatitis C 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Diseases 1

Interventions

Ribavirin 4ledipasvir, sofosbuvir drug combination 2Chromatography, High Pressure Liquid 2tremelimumab 1telaprevir 1sofosbuvir-velpatasvir drug combination 1pembrolizumab 1peginterferon alfa-2a 1ledipasvir 1grazoprevir 1elbasvir-grazoprevir drug combination 1elbasvir 1Sofosbuvir 1Rapid Diagnostic Tests 1Patient Navigation 1Introns 1Infliximab 1Immunoenzyme Techniques 1Hypothermia, Induced 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hepatitis C × ledipasvir, sofosbuvir drug combination × Clear all
NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated
1 enrolled
Lymphoid

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡